These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 12391241

  • 1. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E, Okada CY.
    J Immunol; 2002 Nov 01; 169(9):5227-35. PubMed ID: 12391241
    [Abstract] [Full Text] [Related]

  • 2. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
    Lambert SL, Okada CY, Levy R.
    J Immunol; 2004 Jan 15; 172(2):929-36. PubMed ID: 14707065
    [Abstract] [Full Text] [Related]

  • 3. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
    Wong CP, Okada CY, Levy R.
    J Immunol; 1999 Feb 15; 162(4):2251-8. PubMed ID: 9973501
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM.
    J Immunol; 2008 Sep 15; 181(6):4131-40. PubMed ID: 18768870
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW, Young HA, Pennington RW, Weeks SD.
    Proc Natl Acad Sci U S A; 1996 Oct 01; 93(20):10972-7. PubMed ID: 8855293
    [Abstract] [Full Text] [Related]

  • 11. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.
    Betting DJ, Mu XY, Kafi K, McDonnel D, Rosas F, Gold DP, Timmerman JM.
    Vaccine; 2009 Jan 07; 27(2):250-9. PubMed ID: 19000731
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A.
    Cancer Res; 2001 Sep 01; 61(17):6445-50. PubMed ID: 11522639
    [Abstract] [Full Text] [Related]

  • 14. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z, Kukulansky T, Bar-Or E, Haimovich J, Hollander N.
    J Immunother; 2009 May 01; 32(4):333-40. PubMed ID: 19342972
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P, Pan ZK, Paterson Y.
    Cancer Immunol Immunother; 2008 Apr 01; 57(4):493-505. PubMed ID: 17876582
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines.
    Tanigawa K, Takeshita N, Eickhoff GA, Shimizu K, Chang AE.
    J Immunother; 2001 Apr 01; 24(6):493-501. PubMed ID: 11759072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.